

Jan Westerink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10302/publications.pdf>

Version: 2024-02-01

112
papers

1,768
citations

304368

22
h-index

344852

36
g-index

112
all docs

112
docs citations

112
times ranked

3545
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Diffuse idiopathic skeletal hyperostosis is associated with incident stroke in patients with increased cardiovascular risk. <i>Rheumatology</i> , 2022, 61, 2867-2874. | 0.9 | 9 |
| 2 | Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making. <i>Journal of the American Heart Association</i> , 2022, 11, e017605. | 1.6 | 1 |
| 3 | Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease. <i>PLoS ONE</i> , 2022, 17, e0265050. | 1.1 | 2 |
| 4 | Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. <i>Diabetes Care</i> , 2022, 45, 1211-1218. | 4.3 | 9 |
| 5 | Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research. <i>BMC Public Health</i> , 2022, 22, 660. | 1.2 | 11 |
| 6 | Chronic kidney disease and atrial fibrillation: A dangerous combination. <i>PLoS ONE</i> , 2022, 17, e0266046. | 1.1 | 11 |
| 7 | Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109827. | 1.1 | 8 |
| 8 | Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2022, 100, 77-82. | 1.0 | 14 |
| 9 | Lifestyle changes and kidney function: A 10-year follow-up study in patients with manifest cardiovascular disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13814. | 1.7 | 2 |
| 10 | Post-thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1880-1886. | 1.9 | 9 |
| 11 | The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 322, 251-257. | 0.8 | 13 |
| 12 | Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. <i>International Journal of Cardiology</i> , 2021, 325, 140-148. | 0.8 | 12 |
| 13 | Applicability of Blood Pressure "Lowering Drug Trials to Real-World Patients With Cardiovascular Disease. <i>Hypertension</i> , 2021, 77, 357-366. | 1.3 | 0 |
| 14 | Associations Between Systolic Interarm Differences in Blood Pressure and Cardiovascular Disease Outcomes and Mortality. <i>Hypertension</i> , 2021, 77, 650-661. | 1.3 | 34 |
| 15 | The Impact of a Standardized Pre-visit Laboratory Testing Panel in the Internal Medicine Outpatient Clinic: a Controlled "On-Off" Trial. <i>Journal of General Internal Medicine</i> , 2021, 36, 1914-1920. | 1.3 | 1 |
| 16 | Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia " A Case Study. <i>Frontiers in Physiology</i> , 2021, 12, 638027. | 1.3 | 6 |
| 17 | Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. <i>BMJ Open</i> , 2021, 11, e038881. | 0.8 | 2 |
| 18 | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study. <i>Journal of Nephrology</i> , 2021, 34, 1511-1520. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 1369-1378. | 2.5 | 3 |
| 20 | Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. <i>European Journal of Preventive Cardiology</i> , 2021, , . | 0.8 | 3 |
| 21 | FC 069CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: A DANGEROUS COMBINATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, . | 0.4 | 0 |
| 22 | Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> 2021;44:901â€“907. <i>Diabetes Care</i> , 2021, 44, e139-e139. | 4.3 | 1 |
| 23 | Visceral Adipose Tissue and Different Measures of Adiposity in Different Severities of Diffuse Idiopathic Skeletal Hyperostosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 663. | 1.1 | 14 |
| 24 | Upper Extremity Deep Vein Thrombosis and Asymptomatic Vein Occlusion in Patients With Transvenous Leads: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 698336. | 1.1 | 7 |
| 25 | Variation in perioperative cerebral and hemodynamic monitoring during carotid endarterectomy. <i>Annals of Vascular Surgery</i> , 2021, 77, 153-163. | 0.4 | 4 |
| 26 | The ClearSight system for postoperative arterial blood pressure monitoring after carotid endarterectomy: a validation study. <i>American Journal of Hypertension</i> , 2021, , . | 1.0 | 3 |
| 27 | External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 181. | 2.7 | 0 |
| 28 | Pseudohypoparathyroidism mimicking cervical diffuse idiopathic skeletal hyperostosis with dysphagia: A case report and literature review. <i>Bone Reports</i> , 2021, 15, 101111. | 0.2 | 2 |
| 29 | Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study. <i>European Heart Journal</i> , 2021, 42, . | 1.0 | 0 |
| 30 | Redundant laboratory testing on referral from general practice to the outpatient clinic. <i>BJGP Open</i> , 2021, , BJGPO.2021.0134. | 0.9 | 0 |
| 31 | Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 831-840. | 1.9 | 10 |
| 32 | Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 220. | 2.7 | 59 |
| 33 | Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2020, 38, 45-51. | 0.3 | 5 |
| 34 | Intimal and medial calcification in relation to cardiovascular risk factors. <i>PLoS ONE</i> , 2020, 15, e0235228. | 1.1 | 34 |
| 35 | Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 400-410. | 1.7 | 8 |
| 36 | Standardized reporting of co-morbidity outcome after bariatric surgery: low compliance with the ASMBS outcome reporting standards despite ease of use. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1673-1682. | 1.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy. <i>HemaSphere</i> , 2020, 4, e457. | 1.2 | 5 |
| 38 | Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3842-3853. | 1.8 | 76 |
| 39 | Bempedoic acid: Everything with a place and purpose. <i>European Journal of Preventive Cardiology</i> , 2020, , 2047487320929779. | 0.8 | 1 |
| 40 | Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2341-2348. | 1.9 | 8 |
| 41 | Outcomes of second opinions in general internal medicine. <i>PLoS ONE</i> , 2020, 15, e0236048. | 1.1 | 7 |
| 42 | Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension. <i>BMC Endocrine Disorders</i> , 2020, 20, 56. | 0.9 | 2 |
| 43 | The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. <i>Atherosclerosis</i> , 2020, 301, 37-43. | 0.4 | 24 |
| 44 | Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. <i>Heart</i> , 2020, 106, 1686-1692. | 1.2 | 9 |
| 45 | Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. <i>Blood</i> , 2020, 135, 1377-1385. | 0.6 | 39 |
| 46 | Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6. <i>European Heart Journal</i> , 2020, 41, . | 1.0 | 1 |
| 47 | Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS. <i>European Heart Journal</i> , 2020, 41, . | 1.0 | 0 |
| 48 | External applicability of blood pressure-lowering drug trials to real-world patients with manifest cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, . | 1.0 | 0 |
| 49 | Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease. <i>European Heart Journal</i> , 2020, 41, . | 1.0 | 0 |
| 50 | Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. <i>Diabetes and Metabolism</i> , 2019, 45, 254-260. | 1.4 | 14 |
| 51 | The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 883-890. | 2.2 | 53 |
| 52 | Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial. <i>Diabetes Care</i> , 2019, 42, 1988-1994. | 4.3 | 16 |
| 53 | Transcranial Doppler 24 Hours after Carotid Endarterectomy Accurately Identifies Patients Not at Risk of Cerebral Hyperperfusion Syndrome. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, 320-327. | 0.8 | 18 |
| 54 | Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107880. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | 2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study. <i>European Heart Journal</i> , 2019, 40, . | 1.0 | 2 |
| 56 | The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. <i>European Heart Journal</i> , 2019, 40, 3901-3909. | 1.0 | 54 |
| 57 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a. | 1.0 | 34 |
| 58 | Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. <i>AIDS Reviews</i> , 2019, 20, 205-219. | 0.5 | 4 |
| 59 | Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1935-1943. | 2.2 | 13 |
| 60 | Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 1125-1132. | 1.2 | 30 |
| 61 | P4990Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial. <i>European Heart Journal</i> , 2019, 40, . | 1.0 | 0 |
| 62 | P1540Major adverse limb events (MALE) and the relation with classical risk factors in patients with symptomatic cardiovascular disease. <i>European Heart Journal</i> , 2019, 40, . | 1.0 | 0 |
| 63 | 4943Remnant cholesterol increases the risk for recurrent vascular events independent of LDL-cholesterol in patients with clinical manifest vascular disease. <i>European Heart Journal</i> , 2019, 40, . | 1.0 | 0 |
| 64 | 2180Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, . | 1.0 | 1 |
| 65 | Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 431-440. | 1.2 | 12 |
| 66 | Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1244-1250. | 4.3 | 16 |
| 67 | Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis. <i>International Journal of Cardiology</i> , 2018, 251, 96-102. | 0.8 | 14 |
| 68 | 114Estimating individual cardiovascular disease risk reduction by blood pressure lowering in elderly patients: results from the HYVET study. <i>European Heart Journal</i> , 2018, 39, . | 1.0 | 0 |
| 69 | Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1689-1695. | 4.3 | 63 |
| 70 | Editor's Choice " Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 322-333. | 0.8 | 45 |
| 71 | Combined use of polypill components in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1523-1531. | 0.8 | 8 |
| 72 | The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 23. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1245-1252. | 1.1 | 5 |
| 74 | Anticoagulant bridging in left-sided mechanical heart valve patients. <i>International Journal of Cardiology</i> , 2017, 232, 121-126. | 0.8 | 14 |
| 75 | Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. <i>Journal of Clinical Lipidology</i> , 2017, 11, 12-23.e1. | 0.6 | 33 |
| 76 | Intermittent pneumatic compression in combination with low molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. <i>Journal of Surgical Oncology</i> , 2017, 115, 181-185. | 0.8 | 9 |
| 77 | Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. <i>Journal of Vascular Surgery</i> , 2017, 65, 1519-1527.e26. | 0.6 | 22 |
| 78 | Reply to letter to the Editor "Bridging anticoagulation in patients with mechanical heart valves". <i>International Journal of Cardiology</i> , 2017, 236, 399. | 0.8 | 0 |
| 79 | Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event. <i>American Journal of Cardiology</i> , 2017, 120, 167-173. | 0.7 | 2 |
| 80 | Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease. <i>International Journal of Cardiology</i> , 2017, 244, 271-276. | 0.8 | 30 |
| 81 | Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of) Tj ETQq1 1 0.784314 rgBT /Overlo Multicenter Randomized Controlled Trial "Arteriosclerosis, Thrombosis, and Vascular Biology", 2017, 37, e53. | 1.1 | 1 |
| 82 | Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2017, 248, 301-307. | 0.8 | 27 |
| 83 | Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease. <i>International Journal of Obesity</i> , 2017, 41, 1775-1781. | 1.6 | 7 |
| 84 | Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 320-328. | 2.2 | 3 |
| 85 | Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. <i>Cardiovascular Diabetology</i> , 2017, 16, 134. | 2.7 | 89 |
| 86 | The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101. | 2.7 | 17 |
| 87 | HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1424-1430. | 4.3 | 31 |
| 88 | Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. <i>Circulation</i> , 2016, 134, 1419-1429. | 1.6 | 183 |
| 89 | Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2016;39:1424-1430. <i>Diabetes Care</i> , 2016, 39, e190-e191. | 4.3 | 0 |
| 90 | Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2016, 222, 72-77. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Tendon xanthomas: Not always familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1262-1265. | 0.6 | 14 |
| 92 | Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 412-417. | 1.1 | 45 |
| 93 | Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 486-492. | 0.8 | 2 |
| 94 | The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1127-1127. | 1.7 | 0 |
| 95 | Research update for articles published in <sc>EJCI</sc> in 2013. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1005-1016. | 1.7 | 1 |
| 96 | Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 441-446. | 0.7 | 16 |
| 97 | Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations. <i>Diabetes Care</i> , 2015, 38, 1528-1535. | 4.3 | 17 |
| 98 | Hemoglobin, hematocrit, and changes in cerebral blood flow: the Second Manifestations of ARterial disease-Magnetic Resonance study. <i>Neurobiology of Aging</i> , 2015, 36, 1417-1423. | 1.5 | 24 |
| 99 | Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. <i>Atherosclerosis</i> , 2015, 242, 605-610. | 0.4 | 9 |
| 100 | The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. <i>Diabetes Care</i> , 2015, 38, 1930-1936. | 4.3 | 35 |
| 101 | Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study. <i>Diabetes Care</i> , 2015, 38, 1945-1951. | 4.3 | 17 |
| 102 | Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. <i>International Journal of Obesity</i> , 2015, 39, 265-269. | 1.6 | 21 |
| 103 | An Oral Mixed Fat Load Is Followed by a Modest Anti-inflammatory Adipocytokine Response in Overweight Patients with Metabolic Syndrome. <i>Lipids</i> , 2014, 49, 247-254. | 0.7 | 11 |
| 104 | Premature atherosclerosis, extremely low HDL-cholesterol and concurrent defects in APOA1 and ABCA1 genes: A family case report. <i>International Journal of Cardiology</i> , 2014, 177, e19-e21. | 0.8 | 5 |
| 105 | High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. <i>Atherosclerosis</i> , 2013, 227, 118-124. | 0.4 | 38 |
| 106 | Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1834-1841. | 1.2 | 42 |
| 107 | The Way to a Man's Stomach Is Through His Heart?. <i>Journal of the American College of Cardiology</i> , 2013, 62, 761-762. | 1.2 | 1 |
| 108 | Research update for articles published in <sc>EJCI</sc> in 2011. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1097-1110. | 1.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1240-1249. | 1.7 | 6 |
| 110 | Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 864-873. | 0.8 | 22 |
| 111 | The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. <i>European Journal of Clinical Investigation</i> , 2011, 41, 159-166. | 1.7 | 20 |
| 112 | Pharmacological and non-pharmacological interventions to influence adipose tissue function. <i>Cardiovascular Diabetology</i> , 2011, 10, 13. | 2.7 | 43 |